drugset
drugset / Trial / NCT02273258

A Study to Compare Pharmacokinetics and Pharmacodynamics of SAR342434 to Insulin Lispro in Subjects With Type 1 Diabetes

NCT02273258 ↗

Phase 1 Completed 30 enrolled Sanofi
RandomizedCrossoverDouble-blindTreatment

Summary

Primary Objective: To compare exposure and activity of SAR342434 to US-approved and EU-approved Humalog®. Secondary Objective: To assess the safety and tolerability of SAR342434.

Timeline

Start
2013-03
Primary completion
2013-07
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Insulin Lispro Protein / enzyme biologic — Subcutaneous
Subject SAR342434 Protein / enzyme biologic — Subcutaneous

Indications

type 1 diabetes mellitus